TCT-9 FANTOM II Trial: Safety and Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold: First Report: Final 5-Year Clinical Outcomes
2021
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI